olivLaw · US equity research
GridAI Technologies Corp. GRDX
Electric & Other Services Combined · SIC 4931 · Vertical: Electric & Other Services Combined (SIC 4931)
GridAI Technologies Corp. (formerly Entero Therapeutics) reoriented itself in 2025 toward energy optimization software and orchestration for AI data centers through its acquisition of Grid AI Corp. The company still has a platform without significant revenue and depends on external funding, with serious doubts about going concern that are worth watching for investors and anyone following energy and AI.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, GridAI Technologies Corp. (GRDX) stock was 5.43 USD (+12.42% on the day), with market capitalisation 38.7 m USD, beta 0.71, 52-week range 2.01–6.80 USD. Latest reported quarter (Q2 2026): revenue of 85.9 k USD, net income of -13.0 m USD, diluted EPS -2.01 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 60.5
- strong (55–70)
- Bollinger (20, 2)
- 3.98 – 5.97
- in the upper half of the band · %B 0.73 · band width 40.1%
- SMA 50 / 200
- 4.08 / 3.54
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.35 / 0.39
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +41.8% | −1.1% | +42.9 pp | — |
| 3 months | +96.0% | −0.5% | +96.5 pp | — |
| 6 months | +112.1% | +4.4% | +107.7 pp | — |
| Year to date | +16.5% | +12.3% | +4.2 pp | — |
| 1 year | +33.7% | +13.5% | +20.2 pp | +4.6% |
| 3 years | −71.2% | +76.4% | −147.6 pp | +32.3% |
| 5 years | −100.0% | +63.7% | −163.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 38.2 k | 85.9 k |
| Cost of revenue | — | — | — | — | — | — | 651.9 k | 122.4 k |
| Gross profit | — | — | — | — | — | — | -613.7 k | -36.5 k |
| Research & development | 207.0 k | 21.4 k | 15.8 k | 10.6 k | 6.7 k | 893.4 k | 631.4 k | 8.4 k |
| Operating income | -1.9 m | -1.2 m | -821.4 k | -638.9 k | -934.8 k | -4.7 m | -3.6 m | -13.1 m |
| Depreciation & amortisation | 1.3 k ≈ | 0 | — | — | — | — | — | — |
| Interest expense | -229 | — | 17.9 k | — | — | — | — | — |
| Pre-tax income | -1.9 m | -1.2 m | -948.1 k | -674.9 k | -970.9 k | -4.0 m | -3.7 m | -13.1 m |
| Income tax | 0 ≈ | — | — | 0 | — | — | -297.6 k | -55.5 k |
| Net income | -2.6 m | -12.2 m | -1.3 m | -998.3 k | -1.2 m | -3.0 m | -3.4 m | -13.0 m |
| Diluted EPS | -1.76 | -7.79 ≈ | -0.84 | -0.23 | -0.75 | -1.82 ≈ | -0.82 | -2.01 |
| Operating cash flow | -1.8 m ≈ | -171.5 k | -818.6 k | -54.9 k ≈ | -855.7 k ≈ | -4.0 m | -1.8 m | -1.5 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | unavailable | unavailable | unavailable | unavailable | unavailable | 36.3 k |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -13.5 m | -15.2 m | -32.7 m | -58.5 m | -14.6 m | -15.8 m | -18.1 m | -6.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -14.68 | -1,988.53 | -416.94 | -47.88 | -15.99 | -4.16 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -17,634.4% |
| Free cash flow | -10.9 m | -14.1 m | -11.2 m | -32.4 m | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 899.8 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 24.9 m USD
- Total assets
- 48.6 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.17x
- ROE
- unavailable
- ROA
- -9.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 36.3 k | SEC (XBRL)· 01 May 2026verified |
| Cost of revenue | — | — | — | — | — | 693.7 k | SEC (XBRL)· 01 May 2026verified |
| Gross profit | — | — | — | — | — | -657.4 k | SEC (XBRL)· 01 May 2026verified |
| Research & development | 5.9 m | 17.0 m | 8.8 m | 5.0 m | 903.9 k | 925.5 k | SEC (XBRL)· 01 May 2026verified |
| Operating income | -26.4 m | -59.1 m | -12.7 m | -15.8 m | -15.6 m | -7.1 m | SEC (XBRL)· 01 May 2026verified |
| Depreciation & amortisation | 38.0 k | 15.0 k | 29.0 k | 29.3 k | 48.9 k | 574.7 k | SEC (XBRL)· 01 May 2026verified |
| EBITDA | -26.4 m ≈ | -59.0 m ≈ | -12.6 m ≈ | -15.7 m ≈ | -15.6 m ≈ | -6.5 m ≈ | SEC (XBRL)· 01 May 2026derived |
| Interest expense | 5.8 m | 11.2 k | 15.9 k | 22.5 k | — | — | SEC (XBRL)· 29 Mar 2024verified |
| Pre-tax income | -32.7 m | — | — | — | -15.6 m | -6.6 m | SEC (XBRL)· 01 May 2026verified |
| Income tax | 0 | 0 | — | — | — | -398.7 k | SEC (XBRL)· 01 May 2026verified |
| Net income | -32.7 m | -58.5 m | -14.6 m | -15.8 m | -18.1 m | -6.4 m | SEC (XBRL)· 01 May 2026verified |
| Diluted EPS | -14.68 | -1,988.53 | -416.94 | -47.88 | -15.99 | -4.16 | SEC (XBRL)· 01 May 2026verified |
| Weighted average diluted shares | 2.8 m | 42.5 k | 35.9 k | 336.3 k | 1.1 m | 1.6 m | SEC (XBRL)· 01 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 6.1 m | 8.2 m | 1.4 m | 3.7 m | 163.5 k | 899.8 k | SEC (XBRL)· 01 May 2026verified |
| Receivables | 551.5 k | 0 | 93.0 k | — | 0 | 30.0 k | SEC (XBRL)· 01 May 2026verified |
| Current assets | 7.9 m | 9.4 m | 3.4 m | 5.0 m | 83.5 m | 2.6 m | SEC (XBRL)· 01 May 2026verified |
| Property, plant & equipment, net | 18.3 k | 73.1 k | 43.8 k | 14.6 k | — | — | SEC (XBRL)· 29 Mar 2024verified |
| Goodwill | 2.1 m | 1.9 m | 1.7 m | 1.7 m | 1.7 m | 24.1 m | SEC (XBRL)· 01 May 2026verified |
| Intangibles (excl. goodwill) | 2.9 m | 0 | — | — | 338.4 k | 21.8 m | SEC (XBRL)· 01 May 2026verified |
| Total assets | 12.9 m | 11.8 m | 5.4 m | 6.9 m | 85.4 m | 48.6 m | SEC (XBRL)· 01 May 2026verified |
| Accounts payable | 1.7 m | 2.7 m | 720.0 k | 554.3 k | 3.0 m | 3.4 m | SEC (XBRL)· 01 May 2026verified |
| Current liabilities | 15.5 m | 12.3 m | 2.5 m | 3.1 m | 27.5 m | 15.2 m | SEC (XBRL)· 01 May 2026verified |
| Total liabilities | 15.6 m | 19.6 m | 2.7 m | 3.3 m | 27.6 m | 19.7 m | SEC (XBRL)· 01 May 2026verified |
| Equity | -2.6 m † | -7.8 m † | 2.7 m † | 3.6 m | -3.9 m | 24.9 m | SEC (XBRL)· 01 May 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -11.2 m | -32.3 m | -22.3 m | -12.4 m | -9.2 m | -5.7 m | SEC (XBRL)· 01 May 2026verified |
| Capex | 4.2 k | 69.5 k | — | — | — | — | SEC (XBRL)· 31 Mar 2022verified |
| Free cash flow | -11.2 m ≈ | -32.4 m ≈ | — | — | — | — | SEC (XBRL)· 31 Mar 2022derived |
| Investing cash flow | 87.4 k | -10.3 m | — | -500.0 k | 88.2 k | 323.5 k | SEC (XBRL)· 01 May 2026verified |
| Financing cash flow | 17.0 m | 44.8 m | 15.7 m | 15.2 m | 5.6 m | 5.9 m | SEC (XBRL)· 01 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
3 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 10.6% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 38.7 m USD
Key indicators
Coverage and freshness
Score by group
11% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 10.6% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -56,864.0% | 0 (vs peers) | 60% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.2x | 0 (on a fixed band) | 40% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| Dividend yield · Returns | unavailable | unavailable | — |
| Payout ratio (EPS) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial0/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial0/100 · 1/2 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GridAI Technologies Corp. (GRDX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 36.3 k USD in 2025; net margin -56,864.0%; ROE -480.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 10.6% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -56,864.0%
- Current ratio: 0.2x
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Dividend yield, Payout ratio (EPS).
Versus the vertical median
Electric & Other Services Combined (SIC 4931) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DUKDuke Energy CORP | 101.0 bn | 19.8 | 9.8% | 15.8% | +5.6% | +5% / +40% |
| XELXcel Energy Inc | 51.7 bn | 18.8 | 11.4% | — | +1.2% | −2% / +32% |
| EXCExelon Corporation | 47.3 bn | 16.9 | 9.8% | 11.2% | +5.3% | −2% / +20% |
| EDConsolidated Edison Inc | 44.3 bn | 20.3 | 8.7% | 12.5% | +10.9% | +20% / +34% |
| WECWec Energy Group, Inc. | 38.9 bn | 21.4 | 12.5% | 17.6% | +14.0% | +5% / +41% |
| PEGPublic Service Enterprise Group Incorporated | 36.5 bn | 18.2 | 11.8% | 16.0% | +18.3% | −12% / +17% |
| PCGPg&E Corp | 35.9 bn | 9.6 | 9.7% | 12.3% | +2.1% | −17% / −22% |
| AEEAmeren Corp | 31.3 bn | 19.9 | 12.1% | 17.9% | +15.4% | +6% / +46% |
| CMSCms Energy Corp | 22.3 bn | 21.3 | 11.3% | 11.6% | +13.6% | −6% / +25% |
| NINiSource Inc. | 21.7 bn | 23.1 | 10.1% | 8.2% | +23.5% | +3% / +77% |
| EVRGEvergy, Inc. | 19.9 bn | 22.9 | 8.8% | 14.6% | +2.0% | +11% / +69% |
| LNTAlliant Energy Corp | 19.1 bn | 23.1 | 11.3% | 18.6% | +9.6% | +6% / +46% |
| NWENorthwestern Energy Group, Inc. | 5.0 bn | 29.6 | 5.9% | 10.1% | +6.4% | +19% / +63% |
| AVAAvista Corp | 3.4 bn | 13.5 | 9.0% | 12.8% | +1.3% | −3% / +18% |
| UTLUnitil Corporation | 1.0 bn | 18.3 | 9.0% | 9.1% | +8.3% | +13% / +17% |
| VIVOVivopower PLC | 46.7 m | — | — | -20,970.5% | +281.3% | −42% / −16% |
| GRDXGridAI Technologies Corp. | 38.7 m | — | -480.5% | -56,864.0% | unavailable | +34% / −71% |
| GNEGenie Energy Ltd. | — | 18.0 | 11.2% | 5.1% | +18.1% | +18% / −30% |
1- and 3-year price returns: for GRDX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Aug 2026; since then the company filed 10-Q/A (18 Sept 2026).
In brief
GridAI Technologies Corp. (formerly Entero Therapeutics) reoriented itself in 2025 toward energy optimization software and orchestration for AI data centers through its acquisition of Grid AI Corp. The company still has a platform without significant revenue and depends on external funding, with serious doubts about going concern that are worth watching for investors and anyone following energy and AI.
SWOT
Strengths
- The proposed platform combines data center orchestration with energy optimization, a conceptual advantage if validated commercially.
- The Grid AI Corp. acquisition brought a technical team and technology built for energy and storage markets.
- Adrulipase has a differentiated profile, non-animal-derived and oral, which could reduce the daily pill burden.
Weaknesses
- The company still has insignificant revenue from its core platform and no confirmed major customers.
- There are serious doubts about going concern, and debt went into default before settlement.
- There was significant turnover in management and the board, which complicates governance and execution.
Opportunities
- If a definitive contract with the anchor customer is signed, the company could demonstrate its first revenue from the data center platform.
- Demand from data center operators and energy infrastructure developers could open projects in North America and Australia.
- A strategic partnership or transaction could bring capital and resources for developing Adrulipase or the platform.
Threats
- Difficulty obtaining financing on acceptable terms could force reductions in activity or the end of some programs.
- Competition from large energy and software companies with superior resources could limit market share growth.
- Regulatory changes or delays in project approvals could postpone revenue or alter the business model.
Risks
- Going concernhigh
The company has stated that its dependence on external funding raises substantial doubt about its ability to continue as a going concern.
- Debt in defaulthigh
The revolving loan went into default and settlement required a cash payment and share issuance, which could affect liquidity.
- Dependence on few customersmedium
Future revenue from the AI platform could depend on a small number of customers or projects, and losing them could affect results.
- Exchange listing requirementsmedium
The company received Nasdaq notices in recent years, including for a late annual report, and new non-compliance could lead to delisting proceedings.
- Technology and regulatory uncertaintylow
Platform adoption depends on integration with third-party systems and evolving regulation, which could delay deployments.
Investment thesis
What would need to be true (bull case)
- If the AI data center platform turns its commercial pipeline into definitive contracts, the company could demonstrate a new revenue model relevant to AI-driven energy demand.
- Recognition of the need for energy optimization in AI infrastructure could attract strategic partners to support product development.
- If Adrulipase advances clinically, it could offer a differentiated option for patients with cystic fibrosis and chronic pancreatitis.
What would break the thesis
- The platform has not yet generated significant revenue and the anchor customer has not signed a definitive contract, which could leave the business model unproven.
- The company has going concern doubts and debts that have already gone into default, which could limit strategic options.
- If financing cannot be obtained on acceptable terms, the company could be forced to reduce activities or explore sale or liquidation transactions.
What to watch
- Signing of a definitive commercial contract with the anchor customer for the data center platform2026
- Evolution of funding and liquidity after settlement of the revolving loanQ3 2026
- Compliance with Nasdaq listing requirements and any new notices2026
- Decision on next steps for Adrulipase depending on available capitalnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Aug 2026; since then the company filed 10-Q/A (18 Sept 2026).
The business
GridAI Technologies Corp. is a diversified technology and life sciences company operating through two main areas: energy orchestration and grid optimization software, through its subsidiary Grid AI Corp., and legacy biopharmaceutical development centered on Adrulipase for exocrine pancreatic insufficiency. The acquisition of Grid AI Corp. was completed on September 30, 2025, and the company changed its name and trading symbol at the end of 2025. Grid AI Corp. is developing a platform for AI data centers aimed at using and optimizing distributed energy resources, including battery energy storage, on-site generation and grid interconnections. According to the 10-K, the platform had not generated revenue from this product at the end of 2025, and the company had no major customers at present. This grouping reflects a profound change in business profile and significant funding uncertainties.
The AI data center platform aims to generate revenue through base fees for operational visibility and orchestration, and performance-based fees tied to power cost optimization. The platform includes a digital twin of each site, load and generation forecasting, and a co-optimization engine that participates in energy markets while prioritizing uninterrupted data center operations. The company says an anchor customer, Amp Z, a related party, has collaborated since October 2025, but the parties have not yet concluded a definitive commercial agreement, and material revenue from it has not yet been generated.
The retained biopharmaceutical business centers on Adrulipase, an oral, non-systemic recombinant lipase for patients with cystic fibrosis and chronic pancreatitis. After the ImmunogenX rescission and the discontinuation of the Latiglutenase, CypCel, Capeserod and Niclosamide programs, Adrulipase is the only active biotechnology program. The company has not generated product revenue, and next steps depend on available capital. On the funding side, in 2026 the company defaulted on a revolving loan bearing 18% annual interest and settled the debt through a cash payment and share issuance.
Segments
AI segment (energy and Grid AI Corp.)
The AI segment comprises Grid AI Corp. and its subsidiaries, including AMPX. All 2025 revenue came from this segment, generated mainly from software-enabled orchestration, optimization, dispatch and monitoring services. The AI data center platform is still in development, while the legacy DLS and ALICE products are supported at minimum levels.
Biotechnology segment (Adrulipase)
The GI segment reflects the retained biopharmaceutical activities centered on Adrulipase. It has not generated product revenue, and its research and development spending has declined substantially after the earlier programs were discontinued.
Market context
The market targeted by Grid AI Corp. is energy for AI data centers and other large energy users, especially in North America and Australia. Demand for battery storage and distributed resource optimization is supported by rising electricity needs from AI infrastructure, but market development varies widely by region, and customers have shown reluctance to replace existing systems viewed as effective enough. The company has not yet demonstrated significant commercial volume and aims to prioritize lower-cost, near-term projects.
In the biotechnology segment, the market for exocrine pancreatic insufficiency is dominated by porcine-derived enzyme replacement therapies. Adrulipase aims at a non-animal-derived alternative with potential to reduce daily capsule burden, but the cystic fibrosis and chronic pancreatitis patient populations are relatively narrow and the regulatory path remains uncertain.
Trends
- Rising energy demand from AI data centerstailwind
Expansion of AI infrastructure could increase demand for energy orchestration and battery storage integration if these investments materialize into concrete projects.
- Regulatory complexity in energy marketsheadwind
Rules on distributed energy resources, virtual power plants and wholesale market participation could delay deployments or change the platform's revenue model.
- Adoption of energy optimization technologiesmixed
Growing interest in energy efficiency could support demand, but existing customers appear reluctant to replace functioning systems, which slows adoption.
- Funding pressure on small companiesheadwind
Capital market conditions may limit access to financing, particularly for companies with low revenue and defaulted debt, affecting the ability to execute the plan.
Competitive position
The company states it has not identified a direct competitor offering an equivalent fully integrated solution combining data center orchestration with energy optimization at scale. However, it operates in a broader landscape of partial or adjacent solutions offered by energy, software and industrial companies, some with far greater resources. Competition with battery suppliers and energy infrastructure integrators is relevant to the commercial pipeline.
In biotechnology, Adrulipase competes with existing pancreatic enzyme replacement products, dominated by porcine-based treatments, as well as other therapies in development for exocrine pancreatic insufficiency. Differentiation depends on demonstrating clinical benefit at a development stage that remains uncertain.
- Mango Power
Supplier with which the company has had commercial discussions about battery energy storage systems, named in the 10-K as part of the pipeline.
- Nomad Transportable Power Systems
Transportable energy systems company named among Grid AI Corp.'s discussion partners.
- Porcine pancreatic enzyme replacement producers
Current standard therapies for exocrine pancreatic insufficiency, direct competitors to Adrulipase.
- Energy and software companies with partial solutions
Players in energy, software and industry offering adjacent optimization solutions without full data center integration.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report30 Oct 2026Departure or appointment of officers · Financial statements and exhibits
- Current report28 Oct 2026Material agreement · Financial statements and exhibits
- Current report28 Oct 2026Material agreement · Item 3.02 · Financial statements and exhibits
- Current report23 Oct 2026Departure or appointment of officers
- Current report07 Oct 2026Material agreement · Financial statements and exhibits
- Quarterly report (amendment)18 Sept 2026
- Current report11 Sept 2026Material agreement · Financial statements and exhibits
- Quarterly report21 Aug 2026
- Current report23 Jul 2026Material agreement · Financial statements and exhibits
- Current report (amendment)07 Jul 2026Material agreement · Item 3.02
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / GridAI Technologies Corp. · 01 May 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / GridAI Technologies Corp. · 21 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / GridAI Technologies Corp. · 20 Dec 2018
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.